vimarsana.com

Page 18 - ஹைதராபாத் அடிப்படையிலானது டாக்டர் சிவப்பு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

India reports highest death toll, states see hope only in lockdowns

India To Start Receiving Sputnik V Vaccine Shots This Quarter, Production In India To Start From July

India To Start Receiving Sputnik V Vaccine Shots This Quarter, Production In India To Start From July Russian Sputnik V Covid-19 vaccine (Pic Via Sputnik V website) India is set to receive Russian Vaccine Sputnik V stocks in this quarter, between April and Jun, which was granted emergency use authorisation (EUA) earlier this week on Monday, 12 April reports Times of India. After Covishield and Covaxin, Sputnik V became the third Covid-19 vaccine to be used in the country. As part of its contract with the Russian Direct Investment Fund (RDIF), Hyderabad-based Dr Reddy’s Laboratories (DRL) is expected to receive around 250 million doses of Sputnik V.

Dr Reddy s to also use govt cold chain infra for Sputnik V distribution

Hyderabad-based Dr Reddy’s Laboratories (DRL), the Indian partner for Russia’s Sputnik V, will use the government’s vaccination cold chain infrastructure, along with its own cold chain capabilities, for last-mile distribution of the vaccine in India. Further, 60-70 per cent of Sputnik V’s global production is set to take place in India, said DRL. Sputnik V, a vaccine with 91.6 per cent efficacy the highest among Covid vaccines available in India requires a temperature range of -18 degrees C to -22 degrees C to remain stable. Deepak Sapra, CEO (API and Phar­maceutical Services), DRL, said they have already tested the cold chain infrastructure in India through simulations. “We have tested the cold chain in simulation scenarios from Hyderabad to as far as Manipur in the north-east, Ladakh in the north, and Tamil Nadu in south,” Sapra told reporters on Wednesday.

Covid: Drug regulatory expert panel clears Russia vaccine

India’s drug regulatory expert panel on Monday approved restricted emergency use of Russia’s Sputnik V, paving the way for the entry of a third Covid-19 vaccine in India’s inoculation campaign currently open for people 45 years and older. The subject expert committee (SEC) of the Central Drugs Standard Control Organisation approved an application for the emergency use authorisation for Sputnik V submitted by the Hyderabad-based Dr Reddy’s Laboratories, the PTI reported. The Russia Direct Investment Fund (RDIF), the country’s sovereign wealth fund and the vaccine’s promoter worldwide, and Dr Reddy’s Laboratories, had last year said they would provide India 100 million doses of Sputnik V after its regulatory approval.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.